Get the Stockscreener App
1.68
0.30%
0.01
Adc Therapeutics Sa stock is traded at $1.68, with a volume of 109.75K.
It is up +0.30% in the last 24 hours and down -4.83% over the past month.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
See More
Previous Close:
$1.67
Open:
$1.68
24h Volume:
109.75K
Relative Volume:
0.13
Market Cap:
$161.47M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-0.5695
EPS:
-2.95
Net Cash Flow:
$-121.90M
1W Performance:
+4.69%
1M Performance:
-4.83%
6M Performance:
-43.03%
1Y Performance:
-64.29%
1-Day Range:
$1.65
$1.72
1-Week Range:
$1.62
$1.77
52-Week Range:
$1.39
$5.38
Adc Therapeutics Sa Stock (ADCT) Company Profile
Name
Adc Therapeutics Sa
Sector
Industry
Phone
41 21 653 02 00
Address
BIOPOLE, EPALINGES
Compare ADCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
1.6725 | 161.47M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.12 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.03 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.93 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
249.37 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.25 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-08-24 | Initiated | Stephens | Overweight |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-28-24 | Initiated | Guggenheim | Buy |
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics Sa Stock (ADCT) Latest News
ADC Therapeutics SA (NYSE:ADCT) Short Interest Update - MarketBeat
ADC Therapeutics SA (NYSE:ADCT) Sees Large Drop in Short Interest - Defense World
ADC Therapeutics Appoints Jennifer Herron as Chief Commercial Officer -November 05, 2019 at 06:00 am EST - Marketscreener.com
SG Americas Securities LLC Increases Stock Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADCT stock touches 52-week low at $1.42 amid market challenges - MSN
Investors Don't See Light At End Of ADC Therapeutics SA's (NYSE:ADCT) Tunnel And Push Stock Down 26% - Simply Wall St
Neuroendocrine Tumors Clinical and Non-Clinical Studies, Key - openPR
Is Adc Therapeutics SA (ADCT) a good investment opportunity? - US Post News
Investing in Adc Therapeutics SA (ADCT) Is Getting More Attractive - Knox Daily
Several ADC Therapeutics Insiders Sell Shares Sending Potential Negative Signal - Simply Wall St
Adc Therapeutics SA (ADCT) Shares Down Despite Recent Market Volatility - The News Heater
Adc Therapeutics SA (ADCT) stock analysis: A comprehensive overview - US Post News
Upward Trajectory: Adc Therapeutics SA (ADCT) Posts a Slidee, Closing at 1.58 - The Dwinnex
The Attractiveness of Investing In Adc Therapeutics SA (ADCT) is Growing - Knox Daily
BlackRock, Inc.'s Strategic Acquisition of ADC Therapeutics SA Shares - GuruFocus.com
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan - PR Newswire
Strategic Stock Options Grant: ADC Therapeutics Secures Top Talent with 26.8K Share Package - StockTitan
ADC Therapeutics SA (NYSE:ADCT) Stock Holdings Lifted by JPMorgan Chase & Co. - Defense World
ADC Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference - BioSpace
ADC Therapeutics Takes Center Stage: Key Investor Presentation Coming at Major Biotech Conference - StockTitan
ADCT stock touches 52-week low at $1.66 amid market challenges - MSN
Brokers Set Expectations for ADCT FY2025 Earnings - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Expands By 18.0% - MarketBeat
Barclays PLC Raises Holdings in ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics SA Reveals Preliminary ZYNLONTA Net Sales Information in Recent Corporate Presentation - Defense World
Institutional owners may consider drastic measures as ADC Therapeutics SA's (NYSE:ADCT) recent US$21m drop adds to long-term losses - Simply Wall St
Jane Street Group LLC Buys 38,859 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics Achieves Profitability with ZYNLONTA - TipRanks
ADC Therapeutics : JP Morgan 43rd Annual Healthcare Conference - Marketscreener.com
ADCT Stock Hits 52-Week Low at $1.71 Amid Market Challenges - Investing.com
Geode Capital Management LLC Buys 128,454 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reiterates "Buy" Rating for ADC Therapeutics (NYSE:ADCT) - MarketBeat
Barclays PLC Buys 93,890 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value? - Yahoo Finance
ADC Therapeutics Grants Inducement Stock Options to New Employees in Retention Push | ADCT Stock News - StockTitan
ADC spikes after enrollment update on confirmatory trial for lymphoma therapy - MSN
ADC Therapeutics stock rises on enrollment update (ADCT:NYSE) - Seeking Alpha
ADC Therapeutics SA (NYSE:ADCT) Shares Purchased by State Street Corp - Defense World
Short Interest in ADC Therapeutics SA (NYSE:ADCT) Rises By 36.9% - MarketBeat
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma - PR Newswire
Fmr LLC Takes $167,000 Position in ADC Therapeutics SA (NYSE:ADCT) - Defense World
Charles Schwab Investment Management Inc. Acquires 18,796 Shares of ADC Therapeutics SA (NYSE:ADCT) - Defense World
Top 10 Companies to Watch Out for in Antibody Drug Conjugates - openPR
ADC Therapeutics' SWOT analysis: zynlonta sales challenges offset by expansion hopes - Investing.com
Biocytogen Announces Adcendo ApS Exercises Antibody Option to Accelerate ADC Development - Yahoo Finance UK
Redmile Group, Llc Acquires 100,000 Shares of ADC Therapeutics SA (NYSE:ADCT) Stock - MarketBeat
Research Analysts Issue Forecasts for ADCT FY2024 Earnings - Defense World
Redmile Group, LLC Increases Stake in ADC Therapeutics SA - GuruFocus.com
FY2024 Earnings Estimate for ADCT Issued By HC Wainwright - MarketBeat
Guggenheim Reaffirms “Buy” Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
Adc Therapeutics Sa Stock (ADCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.07%
1.76%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):